Allergan Sales, LLC

Form 483 issued February 27, 2019 · Waco, Texas

Inspection
Jan 29 – Feb 27, 2019
Investigator
Stephen D. Brown
Observations
3
Pages
3
FEI number
1643525

In short: On February 27, 2019, FDA issued a Form 483 with 3 observations to Allergan Sales, LLC in Waco, Texas (FEI 1643525) after an inspection that ran Jan 29 – Feb 27, 2019. The investigator was Stephen D. Brown. Most observations concern facilities & equipment and production; the most-cited regulation is 21 CFR 211.42 (design and construction features).

At a glance

2 of 3 observations on this 483 concern facilities & equipment.

Facilities & equipment2
Production1

What FDA observed

Preview: the opening words of each observation
  1. 01

    Procedures designed to prevent microbiological contamination of drug products purporting to be…

  2. 02

    Aseptic processing areas are deficient regarding the system…

  3. 03

    Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment…

The full 483

Plus the full detail behind each one, exactly as FDA wrote it.

Get the full 483

This inspection in context

Questions about this 483

What did FDA find at Allergan Sales, LLC?

FDA listed 3 observations on this Form 483, mostly about facilities & equipment and production. The most-cited regulation is 21 CFR 211.42 (design and construction features). The opening words of each observation are shown on this page.

Who inspected Allergan Sales, LLC?

Stephen D. Brown is named on this Form 483, for the inspection of Jan 29 – Feb 27, 2019. Each investigator has a profile showing what they cite most.

When was Allergan Sales, LLC inspected by FDA?

The inspection ran Jan 29 – Feb 27, 2019, and the Form 483 is dated February 27, 2019.

How do I get the full Form 483 for Allergan Sales, LLC?

Download the original PDF from FDA Intel for $99, with no subscription. Your first Form 483 or letter is on us. You also get an invoice PDF with the order.

$99Get it free